Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Argenx SE. (2/28/19). "Press Release: Argenx Reports Fourth Quarter Business Update and Full Year 2018 Financial Results". Breda & Ghent.

Organisation Organisation Argenx SE (Euronext + Nasdaq: ARGX)
  Group Argenx (Argen-X) (Group)
Products Product cusatuzumab (ARGX-110)
  Product 2 ABBV-151 (formerly ARGX-115 SIMPLE antibody)
Index term Index term AbbVie–Argenx: SIMPLE antibodies, 201604– collob $40m upfront + $645m milestones + royalties developm + commerc of ARGX-115
Person Person Van Hauwermeiren, Tim (Argen-X 201101 CEO before Ablynx BusDev Manager before P&G)
     


argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced its fourth quarter business update and full year results for 2018.

The full year results will be discussed during a conference call and webcast presentation today at 3 pm CET/9 am EST. To participate in the conference call, please select your phone number below and use the confirmation code 9795988. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

“By translating fundamental immunology breakthroughs into novel product candidates, we have built a robust pipeline of differentiated antibodies with the potential to truly impact patients' lives,” commented Tim Van Hauwermeiren, CEO of argenx. “We made great progress in 2018 with our wholly owned lead asset efgartigimod, advancing development across four severe autoimmune indications, in both intravenous and subcutaneous formulations. We signed a transformational global collaboration and license agreement with Janssen to develop cusatuzumab in AML while retaining key commercial rights to the product in the U.S. We also announced that AbbVie exercised its option to in-license ARGX-115 targeting GARP.

“Based on our deep and diversified product candidate portfolio, a solid cash position and an ambitious business plan we are facing an abundance of opportunity ahead in 2019. We will continue to build out our novel pipeline through our Innovative Access Program and our commercial capabilities as we drive enrollment of the Phase 3 ADAPT trial of efgartigimod in gMG and plan for the start of a second Phase 3 trial in ITP.”

FOURTH QUARTER 2018 AND RECENT HIGHLIGHTS

See full version of PR in Download section of this page.


Downloads

PR argenx reports fourth quarter business update and full year 2018 financial results [ http://www.argenx.com/handlers/download.ashx?filename=%2fckfinder%2fuserfiles%2ffiles%2fpress-releases%2fpr190228-argenx-announces-fy-results-and-q4-business-update-final.pdf ]

Y2018 Consolidated Financial Statements argenx SE [ http://www.argenx.com/handlers/download.ashx?filename=%2fckfinder%2fuserfiles%2ffiles%2fpress-releases%2fconsolidated-financial-statements-argenx-se-december-31-2018.pdf ]

   
Record changed: 2019-03-06

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Argenx (Argen-X) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px




» top